Antimicrobial Stewardship at the Core of COVID-19 Response Efforts: Implications for Sustaining and Building Programs
Overview
Authors
Affiliations
We describe traditional antimicrobial stewardship program (ASP) activities with a discussion of how these activities can be refocused in the setting of the COVID-19 pandemic. Additionally, we discuss possible adverse consequences of ASP attention diversion on COVID-19 response efforts and overall implications for future pandemic planning. We also discuss ASP in collaboration with other groups within health systems and how COVID-19 may affect these relationships long term. Despite the paucity of literature on Antimicrobial Stewardship and COVID-19, the potential contributions of ASPs during a pandemic are numerous. ASPs can develop strategies to identify patients with COVID-19-like-illness; this is particularly useful when these patients are missed at the time of health system entry. ASPs can also play a critical role in the management of potential drug shortages, developing local treatment guidelines, optimizing the use of antibiotics, and in the diagnostic stewardship of COVID-19 testing, among other roles. Importantly, it is often difficult to ascertain whether critically ill patients who are hospitalized with COVID-19 have concurrent or secondary bacterial infections-ASPs are ideally situated to help optimize antimicrobial use for these patients via a variety of mechanisms. ASPs are uniquely positioned to aid in pandemic response planning and relief efforts. ASPs are already integrated into health systems and play a key role in optimizing antimicrobial prescribing. As ASPs assist in COVID-19 response, understanding the role of ASPs in pandemic relief efforts may mitigate damage from future outbreaks.
Antimicrobial use before and during COVID-19: data from 108 Veterans Affairs medical centers.
Goetz M, Willson T, Rubin M, Stevens V, Graber C Antimicrob Steward Healthc Epidemiol. 2025; 4(1):e109.
PMID: 39823121 PMC: 11736461. DOI: 10.1017/ash.2024.352.
COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.
Bou-Antoun S, Rokadiya S, Ashiru-Oredope D, Demirjian A, Sherwood E, Ellaby N J Antimicrob Chemother. 2023; 78(Suppl 2):ii37-ii42.
PMID: 37995354 PMC: 10666993. DOI: 10.1093/jac/dkad314.
Antibiotic Use Among Hospitalized Patients With COVID-19 in the United States, March 2020-June 2022.
Kim C, Wolford H, Baggs J, Reddy S, Hicks L, Neuhauser M Open Forum Infect Dis. 2023; 10(11):ofad503.
PMID: 37942462 PMC: 10629359. DOI: 10.1093/ofid/ofad503.
Geng Y, Li F, Chen C, Liu Z, Ma X, Su X Infect Drug Resist. 2023; 16:4707-4716.
PMID: 37492798 PMC: 10364815. DOI: 10.2147/IDR.S421240.
Nasr Z, Elamin W, Basil M, Eljaaly K Int J Clin Pharm. 2023; 45(3):613-621.
PMID: 37162655 PMC: 10171144. DOI: 10.1007/s11096-023-01574-0.